Kyverna Therapeutics

About:

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

Top Investors: Insight Partners, RTW Investments, Gilead Sciences, Intellia Therapeutics, Northpond Ventures

Description:

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

Total Funding Amount:

$170M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Berkeley, California, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)kyvernatx.com

Founders:

Jeffrey Greve

Number of Employees:

51-100

Last Funding Date:

2023-08-03

IPO Status:

Public

Industries: